Peptide-binding groove of Major Histocompatibility Complex (MHC) class I and class II molecules (MHC peptide-binding groove)

The peptide-binding groove of Major Histocompatibility Complex (MHC) class I and class II molecules is a specialized structural domain responsible for presenting antigenic peptides to T cells (1.1.2). MHC class I molecules (HLA-A, -B, -C) typically bind short peptides of 8-10 amino acids derived from endogenous proteins and present them to CD8+ cytotoxic T cells (1.1.3, 1.4.1). In contrast, MHC class II molecules (HLA-DR, -DP, -DQ) bind longer peptides of 13-25 amino acids from exogenous sources for presentation to CD4+ helper T cells (1.1.4, 1.2.4). This groove is formed by two alpha-helices resting on a floor of beta-sheets, creating a cleft that determines immune specificity through polymorphic anchor pockets (1.2.1, 1.2.2). In therapeutic contexts, the groove is targeted by peptide-based vaccines to induce specific immunity and by immunomodulators like glatiramer acetate, which competes for binding to suppress autoimmune responses in multiple sclerosis (1.3.1, 1.3.3). Additionally, certain small molecules like abacavir can bind within the groove, altering the repertoire of presented self-peptides and triggering severe hypersensitivity reactions in genetically predisposed individuals (1.4.2, 1.4.4). The structural integrity and peptide-loading efficiency of the groove are critical for effective immune surveillance and the prevention of immune evasion by cancers (1.2.3, 1.4.4).

Other names

HLA peptide-binding cleftMHC binding pocketAntigen-binding grooveMHC peptide-binding cleftHLA-binding grooveAntigen-presenting cleft

Competitive inhibition of peptide binding, alteration of the presented peptide repertoire (altered self-peptide presentation), and enhancement of peptide loading or exchange.